Levotofisopam

Levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative. It has been investigated primarily for its uricosuric activity in patients with hyperuricemia and gout, where it lowers serum uric acid levels by increasing the fractional excretion of uric acid. Unlike traditional benzodiazepines, levotofisopam is nonsedating and has also been prescribed outside the United States for stress-related disorders such as anxiety, functional gastrointestinal disorders, and menopausal symptoms. Its mechanism involves interaction with subcortical 2,3-benzodiazepine receptors and possibly GABAA receptors. The drug was initially developed by W World Corp., later advanced in clinical trials by Vela Pharmaceuticals (which merged with Pharmos Corporation). Clinical studies have shown that levotofisopam is generally well tolerated[1][3][4][5][6].

Other names

levotofisopam